ASH 2023 | Stratification of patients with multiple myeloma using R2-ISS predicts outcomes of autoSCT
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses outcomes for patients with multiple myeloma (MM) who have received autologous stem cell transplantation (autoSCT) and are stratified according to the second revision of the International Staging System (R2-ISS). This study found that R2-ISS is a reliable prognostic tool, with patients in lower stages having significantly better progression-free survival (PFS) and overall survival (OS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.”
Disclosures
Advisory board: Bioline
Research Funding: Amgen, Janssen, Angiocrine, NexImmune
